Home/Pipeline/CHK1 Inhibitor Program

CHK1 Inhibitor Program

Oncology

PreclinicalActive

Key Facts

Indication

Oncology

Phase

Preclinical

Status

Active

Company

Sareum

About Sareum

Sareum Holdings PLC is a public, clinical-stage biotech developing novel kinase inhibitors with a primary focus on dual TYK2/JAK1 inhibition for autoimmune conditions and cancer. Its lead asset, SDC-1801, is advancing through Phase 2-enabling studies, while a second program targets the CHK1 kinase in oncology. Headquartered in Cambridge, UK, the company leverages its expertise in kinase biology to pursue best-in-class therapeutic candidates in high-value markets, though it remains pre-revenue and faces the typical risks of drug development.

View full company profile

Therapeutic Areas

Autoimmune Diseases Oncology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active